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Clinical PerspectiveWhat Is New?Inherited thrombophilias (factor V Leiden, prothrombin G20210A mutation, protein C deficiency, and protein S deficiency) are associated with an increased risk of arterial ischemic stroke in adults, particularly in younger adults.What Are the Clinical Implications?The role of inherited thrombophilia testing in patients with ischemic stroke as well as its influence on clinical management warrant further study.

Introduction {#jah34477-sec-0008}
============

The inherited thrombophilias, factor V Leiden (FVL), the prothrombin G20210A mutation (PTM), protein C deficiency (PCD), protein S deficiency (PSD), and antithrombin deficiency (ATD), are well‐established predisposing factors for venous thromboembolism,[1](#jah34477-bib-0001){ref-type="ref"}, [2](#jah34477-bib-0002){ref-type="ref"} but their role in arterial thrombosis, such as arterial ischemic stroke, remains uncertain.

In patients with arterial ischemic stroke, inherited thrombophilia testing is often ordered to identify the cause of stroke. However, the benefit of screening for inherited thrombophilia is unknown and such practice is controversial.[3](#jah34477-bib-0003){ref-type="ref"}, [4](#jah34477-bib-0004){ref-type="ref"} Indeed, the 2018 American Heart Association/American Stroke Association clinical practice guideline recommends against thrombophilia testing in patients with ischemic stroke,[5](#jah34477-bib-0005){ref-type="ref"} although such testing remains common in clinical practice.[6](#jah34477-bib-0006){ref-type="ref"}

Current evidence about the association of inherited thrombophilia and the risk of ischemic stroke is conflicting.[7](#jah34477-bib-0007){ref-type="ref"} Individual studies carry the limitations of small sample size and reduced statistical power. Therefore, we conducted a systematic review and meta‐analysis to evaluate the association of inherited thrombophilia (FVL, PTM, PCD, PSD, and ATD) and the risk of arterial ischemic stroke in adults.

Methods {#jah34477-sec-0009}
=======

The study protocol is registered on PROSPERO (CRD42018090020). We followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses[8](#jah34477-bib-0008){ref-type="ref"} and the Meta‐Analysis of Observational Studies in Epidemiology guidelines.[9](#jah34477-bib-0009){ref-type="ref"} The data that support the findings of this study are available from the corresponding author on request.

Data Sources and Search Strategies {#jah34477-sec-0010}
----------------------------------

We searched PubMed, EMBASE, and the Cochrane Library Databases from inception to December 31, 2018. The following search terms were used: "stroke" OR "cerebrovascular accident" AND "factor V" OR "prothrombin" OR "antithrombin" OR "protein C" OR "protein S" OR "thrombophilia." No language restriction was applied. The detailed search queries are presented in Data [S1](#jah34477-sup-0001){ref-type="supplementary-material"}. Additional searches were performed by manual review of abstracts from the American Society of Hematology annual meeting, the Congress of the International Society on Thrombosis and Hemostasis, the American Academy of Neurology annual meeting, and the International Stroke Conference (from 2015 to 2018). Reference lists of relevant studies and review articles were screened for potentially eligible studies.

Study Selection {#jah34477-sec-0011}
---------------

Two authors (T.C., E.D.) independently searched the literature, screened titles and abstracts, and reviewed full texts to identify potentially eligible studies. Disagreements were resolved by consensus or a third reviewer (A.C.) when necessary.

The primary outcome of interest was arterial ischemic stroke. Eligible studies included case‐control or cohort studies of adults, aged ≥15 years, that reported the prevalence of at least one of the inherited thrombophilias of interest (FVL, PTM, PCD, PSD, or ATD) in both subjects with a history of arterial ischemic stroke and subjects without arterial ischemic stroke. Both prospective and retrospective studies were included. Studies were required to have ≥10 subjects in each group. Studies that enrolled patients with transient ischemic attack, hemorrhagic stroke, cerebral venous sinus thrombosis, and other arterial thromboses were excluded unless data for arterial ischemic stroke could be disaggregated. Studies that included neonates or children were also excluded.

If multiple studies used the same or overlapping samples, we included only the one with the largest sample size in the quantitative analysis. Cohen\'s κ coefficient was calculated to evaluate interobserver agreement for study selection.

We did not attempt to control for method used to diagnose thrombophilia, nor did we limit how the control population was constituted, assuming it appeared to be a valid comparator group.

Data Extraction {#jah34477-sec-0012}
---------------

Two authors (T.C., E.D.) independently extracted data from included studies in duplicate using a standardized evidence table. Discrepancies were resolved by consensus or a third reviewer (A.C.) when necessary. The following data were collected: study period, country of study, number of cases and controls, case and control identification method, method of stroke diagnosis, matched variables for cases and controls, baseline characteristics of cases and controls (eg, age, sex, ethnicity, and cardiovascular risk factors), type(s) of thrombophilia reported, methods and timing of thrombophilia testing, and number of cases and controls testing positive and negative for each type of thrombophilia.

Quality Assessment {#jah34477-sec-0013}
------------------

Methodological quality assessment was performed independently by 2 authors (T.C., E.D.) using either the National Institutes of Health--National Heart, Lung, and Blood Institute Quality Assessment of Case‐Control Studies assessment tool[10](#jah34477-bib-0010){ref-type="ref"} or the National Institutes of Health--National Heart, Lung, and Blood Institute Quality Assessment for Observational Cohort and Cross‐Sectional Studies assessment tool,[11](#jah34477-bib-0011){ref-type="ref"} as appropriate. Studies were categorized by their risk of bias as good, fair, or poor quality. Any differences in quality rating were resolved by consensus or adjudication by a third reviewer (A.C.).

Statistical Analysis {#jah34477-sec-0014}
--------------------

Data analysis was performed using R, Version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). Pooled odds ratios (ORs) and 95% CIs were calculated using the bayesian method with random‐effects model. Interstudy heterogeneity was evaluated using the Cochran Q test and I^2^ statistic. A Cochran Q test *P*\<0.05 is considered significant for heterogeneity. An I^2^ value of 0% to 25% represents insignificant heterogeneity, 26% to 50% represents low heterogeneity, 51% to 75% represents moderate heterogeneity, and \>75% represents high heterogeneity. For FVL and PTM, separate analyses for homozygosity and heterozygosity were performed if studies provided stratified data by zygosity status. Prespecified subgroup analyses were performed in young patients (aged \<65 years), patients with a patent foramen ovale (PFO), and patients with cryptogenic stroke, where reported. Sensitivity analyses were performed between age‐matched versus non--age‐matched studies and studies among different continents. Funnel plots of OR versus SE and Egger\'s test for asymmetry were used to assess for the presence of publication bias. *P*\<0.05 was considered statistically significant. When publication bias was detected, Copas selection model was used and adjusted pooled ORs were reported to estimate the effect of publication bias on the results.[12](#jah34477-bib-0012){ref-type="ref"}

Results {#jah34477-sec-0015}
=======

Study Identification {#jah34477-sec-0016}
--------------------

The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram is shown in Figure [1](#jah34477-fig-0001){ref-type="fig"}. A total of 1875 records were retrieved from the literature search. After screening by title and abstract, 1661 records were excluded. The remaining 214 references underwent full‐text review, 68 of which met eligibility criteria and were included in the analysis. These 68 studies collectively enrolled 11 916 stroke patients and 96 057 controls. All 68 studies were case‐control studies. We did not identify any cohort studies that met eligibility criteria. The complete list of included studies is provided in Supplemental References. The number of studies that reported on FVL, PTM, PCD, PSD, and ATD were 56, 45, 15, 17, and 12, respectively. There was excellent agreement between the 2 independent reviewers with respect to study selection (κ=0.96).

![Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram. ATD indicates antithrombin deficiency; FVL, factor V Leiden; PCD, protein C deficiency; PSD, protein S deficiency; PTM, prothrombin G20210A mutation; TIA, transient ischemic attack.](JAH3-8-e012877-g001){#jah34477-fig-0001}

Study Characteristics {#jah34477-sec-0017}
---------------------

Characteristics of included studies are listed in Tables [S1](#jah34477-sup-0001){ref-type="supplementary-material"} and [S2](#jah34477-sup-0001){ref-type="supplementary-material"}. The results from individual studies are listed in Tables [S3](#jah34477-sup-0001){ref-type="supplementary-material"} through [S7](#jah34477-sup-0001){ref-type="supplementary-material"}. We included 64 case‐control and 4 nested case‐control studies. One study was published as a conference abstract.

The publication year of included studies ranged from 1993 to 2017. Twenty‐eight studies enrolled only young and middle‐aged adults, with an upper age limit ranging from 40 to 65 years. All included studies enrolled ≥20 cases and controls, with most (87% of studies) enrolling \>40 subjects in each group. A few studies focused on specific subgroups with certain comorbidities, such as atrial fibrillation,[13](#jah34477-bib-0013){ref-type="ref"} HIV infection,[14](#jah34477-bib-0014){ref-type="ref"}, [15](#jah34477-bib-0015){ref-type="ref"} and systemic lupus erythematosus.[16](#jah34477-bib-0016){ref-type="ref"} Most studies recruited healthy subjects in the same geographic area as controls. In 4 studies, historical controls were used, whereas the remaining 64 studies recruited contemporaneous controls. Although most studies matched cases and controls by age and sex, only 4 studies matched by ethnicity and only 1 study matched controls for the presence of cardiovascular risk factors.[17](#jah34477-bib-0017){ref-type="ref"} A comparison of demographic data and clinical risk factors between cases and controls in each study is listed in Table [S2](#jah34477-sup-0001){ref-type="supplementary-material"}. Most studies did not provide detailed information about clinical risk factors in the control group. When reported, clinical stroke risk factors, such as hypertension, diabetes mellitus, and smoking, were more frequent in cases than controls in most studies.

Ischemic stroke was diagnosed by neuroimaging in most studies. In 9 studies, the method of diagnosis was not described. One epidemiologic study used self‐reported history of stroke to define cases.[18](#jah34477-bib-0018){ref-type="ref"} Studies varied in terms of stroke subtypes included. Some exclusively enrolled cases with cryptogenic stroke,[19](#jah34477-bib-0019){ref-type="ref"}, [20](#jah34477-bib-0020){ref-type="ref"}, [21](#jah34477-bib-0021){ref-type="ref"}, [22](#jah34477-bib-0022){ref-type="ref"}, [23](#jah34477-bib-0023){ref-type="ref"}, [24](#jah34477-bib-0024){ref-type="ref"}, [25](#jah34477-bib-0025){ref-type="ref"} whereas in other studies, the proportion of cryptogenic stroke among cases ranged from 6% to 55% when reported. In 24 studies, only cases with first‐ever ischemic stroke were included. Forty‐one studies did not specify whether recurrent stroke was included, whereas 3 studies included cases of both first‐ever and recurrent stroke (16%--42% of cases), but did not provide disaggregated data for the recurrent stroke group.[26](#jah34477-bib-0026){ref-type="ref"}, [27](#jah34477-bib-0027){ref-type="ref"}, [28](#jah34477-bib-0028){ref-type="ref"} Almost all of the included studies reported use of standard and widely accepted test methods for the diagnosis of thrombophilia (Table [S3](#jah34477-sup-0001){ref-type="supplementary-material"} through [S7](#jah34477-sup-0001){ref-type="supplementary-material"}).

Quality Appraisal {#jah34477-sec-0018}
-----------------

Using the National Institutes of Health--National Heart, Lung, and Blood Institute Quality Assessment of Case‐Control Studies tool, the included studies were rated as good (N=22), fair (N=43), and poor (N=3) quality. The studies with good, fair, and poor rating contributed 31%, 56%, and 13% of cases and 9%, 90%, and 1% of controls, respectively. Details of study quality assessment items for each study are reported in Table [S8](#jah34477-sup-0001){ref-type="supplementary-material"}.

Studies with a good quality rating carry the least risk of bias. Studies were rated as fair quality when they were susceptible to some degree of bias. These included studies that did not recruit cases and controls from the same population, studies that did not match controls or did not adjust for confounders, and studies that did not specify valid and reliable methods of stroke diagnosis or thrombophilia testing. Studies were rated as poor quality when the definition of cases and controls was not explicitly described.

Genetic testing was used to identify FVL and PTM, whereas functional tests were used in most studies to identify PCD, PSD, and ATD. Protein C, protein S, and antithrombin levels may be reduced in the setting of anticoagulant therapy and acute thromboembolism. Eight of the studies excluded patients receiving anticoagulants, whereas 9 studies did not specifically mention anticoagulant use. All but 2 studies required testing at a distant time from the stroke event (with time frames ranging from 2 days to 6 months) or a second confirmatory test if the first one was abnormal. Although several studies reported blinding of exposure assessor to case/control status,[17](#jah34477-bib-0017){ref-type="ref"}, [20](#jah34477-bib-0020){ref-type="ref"}, [25](#jah34477-bib-0025){ref-type="ref"}, [27](#jah34477-bib-0027){ref-type="ref"}, [29](#jah34477-bib-0029){ref-type="ref"}, [30](#jah34477-bib-0030){ref-type="ref"}, [31](#jah34477-bib-0031){ref-type="ref"}, [32](#jah34477-bib-0032){ref-type="ref"}, [33](#jah34477-bib-0033){ref-type="ref"}, [34](#jah34477-bib-0034){ref-type="ref"}, [35](#jah34477-bib-0035){ref-type="ref"}, [36](#jah34477-bib-0036){ref-type="ref"} most did not specify whether the assessor was blinded.

Thrombophilia and Arterial Ischemic Stroke {#jah34477-sec-0019}
------------------------------------------

The pooled ORs of arterial ischemic stroke for each thrombophilia are summarized in Figure [2](#jah34477-fig-0002){ref-type="fig"}.

![Forest plot showing association between inherited thrombophilia and risk of arterial ischemic stroke. The forest plot shows the results from the meta‐analysis for each type of thrombophilia and its association with arterial ischemic stroke. The pooled odds ratio (OR) is represented by the square box. The whiskers represent 95% CIs. The I^2^ statistic was used to evaluate study heterogeneity. FVL indicates factor V Leiden; PTM, prothrombin G20210A mutation.](JAH3-8-e012877-g002){#jah34477-fig-0002}

### Factor V Leiden {#jah34477-sec-0020}

FVL was assessed in 56 studies (10 229 cases and 31 816 controls), 49 of which reported homozygosity and heterozygosity status. FVL, irrespective of zygosity status, was found in significantly more arterial ischemic stroke cases than controls, with a pooled OR of 1.25 (95% CI, 1.08--1.44). Heterogeneity among studies was insignificant (*P*=0.93; I^2^=0%). The forest plot is shown in Figure [S1](#jah34477-sup-0001){ref-type="supplementary-material"}.

For homozygous FVL, the pooled OR was 0.72 (95% CI, 0.39--1.34; I^2^=0%) (Figure [S2](#jah34477-sup-0001){ref-type="supplementary-material"}). Of 49 studies that tested for FVL, 33 (67%) did not identify homozygous FVL in any of the cases or controls. When such studies with zero events were excluded from the analysis, the pooled OR for homozygous FVL was 2.24 (95% CI, 1.26--4.71). For heterozygous FVL, the pooled OR was 1.23 (95% CI, 1.05--1.45; I^2^=0%) (Figure [S3](#jah34477-sup-0001){ref-type="supplementary-material"}).

A funnel plot was symmetrical (Figure [S4](#jah34477-sup-0001){ref-type="supplementary-material"}A) and Egger\'s test was nonsignificant (*P*=0.46), suggesting absence of publication bias.

### Prothrombin G20210A mutation {#jah34477-sec-0021}

PTM was assessed in 45 studies (7921 cases and 83 574 controls), 39 of which reported homozygosity and heterozygosity status. PTM, irrespective of zygosity status, was found in significantly more arterial ischemic stroke cases than controls, with a pooled OR of 1.48 (95% CI, 1.22--1.80). Heterogeneity among studies was insignificant (*P*=0.93; I^2^=0%). The forest plot is shown in Figure [S5](#jah34477-sup-0001){ref-type="supplementary-material"}.

For homozygous PTM, the pooled OR was 0.31 (95% CI, 0.11--0.83; I^2^=35%) (Figure [S6](#jah34477-sup-0001){ref-type="supplementary-material"}). Of 39 studies that tested for PTM, 31 (79%) did not identify homozygous PTM in any of the cases or controls. When such studies with zero events were excluded from the analysis, the pooled OR for homozygous PTM was 7.19 (95% CI, 2.47--20.94). For heterozygous PTM, the pooled OR was 1.41 (95% CI, 1.13--1.76; I^2^=0%) (Figure [S7](#jah34477-sup-0001){ref-type="supplementary-material"}).

A funnel plot was symmetrical (Figure [S4](#jah34477-sup-0001){ref-type="supplementary-material"}B) and Egger\'s test was nonsignificant (*P*=0.05), suggesting absence of publication bias.

### Protein C deficiency {#jah34477-sec-0022}

Protein C was measured in 15 studies (1676 cases and 11 895 controls). Of these studies, 7 excluded patients receiving anticoagulants, whereas 8 did not specifically mention anticoagulant use. PCD was found in significantly more arterial ischemic stroke cases than controls, with a pooled OR of 2.13 (95% CI, 1.16--3.90) (Figure [S8](#jah34477-sup-0001){ref-type="supplementary-material"}). Heterogeneity among studies was insignificant (*P*=0.52; I^2^=0%). A funnel plot was symmetrical (Figure [S4](#jah34477-sup-0001){ref-type="supplementary-material"}C) and Egger\'s test was nonsignificant (*P*=0.05), suggesting absence of publication bias.

### Protein S deficiency {#jah34477-sec-0023}

Protein S was measured in 16 studies (1803 cases and 6133 controls). Of these studies, 8 excluded patients receiving anticoagulants, whereas 8 did not specifically mention anticoagulant use. PSD was found in significantly more arterial ischemic stroke cases than controls, with a pooled OR of 2.26 (95% CI, 1.34--3.80) (Figure [S9](#jah34477-sup-0001){ref-type="supplementary-material"}). Heterogeneity among studies was insignificant (*P*=0.31; I^2^=8.8%). A funnel plot was symmetrical (Figure [S4](#jah34477-sup-0001){ref-type="supplementary-material"}D) and Egger\'s test was nonsignificant (*P*=0.45), suggesting absence of publication bias.

### Antithrombin deficiency {#jah34477-sec-0024}

Antithrombin was measured in 12 studies (1407 cases and 11 796 controls). Of these studies, 5 excluded patients receiving anticoagulants, whereas 7 did not specifically mention anticoagulant use. ATD was numerically more common in arterial ischemic stroke cases than controls, but statistical significance was not reached (pooled OR, 1.25; 95% CI, 0.58--2.67) (Figure [S10](#jah34477-sup-0001){ref-type="supplementary-material"}). Heterogeneity among studies was insignificant (*P*=0.22; I^2^=8.8%). A funnel plot was asymmetrical (Figure [S4](#jah34477-sup-0001){ref-type="supplementary-material"}E) and Egger\'s test was significant (*P*=0.01), suggesting possible publication bias. The pooled OR adjusted for publication bias using the Copas selection model was 1.39 (95% CI, 0.34--5.73).

Subgroup Analyses {#jah34477-sec-0025}
-----------------

We conducted prespecified subgroup analyses in young patients (aged ≤65 years), patients with a PFO, and patients with cryptogenic stroke. Results of these subgroup analyses for each thrombophilia are summarized in Figure [3](#jah34477-fig-0003){ref-type="fig"}.

![Forest plot showing pooled odds ratio (OR) for each thrombophilia in specific subgroups of patients. The forest plot shows the results from the prespecified subgroup analyses for each type of thrombophilia. The pooled ORs are represented by the square boxes. The horizontal lines represent the 95% CIs. PFO indicates patent foramen ovale.](JAH3-8-e012877-g003){#jah34477-fig-0003}

### Young patients {#jah34477-sec-0026}

Twenty‐eight studies exclusively enrolled young patients (aged ≤65 years). In the subgroup of young patients, the association of FVL, PTM, PCD, and PSD and arterial ischemic stroke remained significant. In general, the pooled ORs for young patients were greater than the overall pooled ORs across all thrombophilias (Figure [3](#jah34477-fig-0003){ref-type="fig"} and Figures [S11](#jah34477-sup-0001){ref-type="supplementary-material"} through [S15](#jah34477-sup-0001){ref-type="supplementary-material"}).

### Patients with PFO {#jah34477-sec-0027}

Two studies[25](#jah34477-bib-0025){ref-type="ref"}, [37](#jah34477-bib-0037){ref-type="ref"} exclusively enrolled patients with PFO, whereas two[21](#jah34477-bib-0021){ref-type="ref"}, [38](#jah34477-bib-0038){ref-type="ref"} reported disaggregated data for cases with and without PFO. A significant association between thrombophilia and arterial ischemic stroke was not detected in the subgroups of patients with PFO, except for PTM (OR, 2.62; 95% CI, 1.11--6.16) (Figure [3](#jah34477-fig-0003){ref-type="fig"} and Figures [S11](#jah34477-sup-0001){ref-type="supplementary-material"} through [S15](#jah34477-sup-0001){ref-type="supplementary-material"}).

### Patients with cryptogenic stroke {#jah34477-sec-0028}

Seven studies[19](#jah34477-bib-0019){ref-type="ref"}, [20](#jah34477-bib-0020){ref-type="ref"}, [21](#jah34477-bib-0021){ref-type="ref"}, [22](#jah34477-bib-0022){ref-type="ref"}, [23](#jah34477-bib-0023){ref-type="ref"}, [24](#jah34477-bib-0024){ref-type="ref"}, [25](#jah34477-bib-0025){ref-type="ref"} exclusively enrolled patients with cryptogenic stroke. A significant association between thrombophilia and arterial ischemic stroke was not detected in the subgroups of patients with cryptogenic stroke (Figure [3](#jah34477-fig-0003){ref-type="fig"} and Figures [S11](#jah34477-sup-0001){ref-type="supplementary-material"} through [S15](#jah34477-sup-0001){ref-type="supplementary-material"}).

Sensitivity Analyses {#jah34477-sec-0029}
--------------------

We prespecified sensitivity analyses according to geographic region and whether studies used age‐matched versus non--age‐matched controls.

### Age‐matched versus unmatched controls {#jah34477-sec-0030}

The number of studies with and without age‐matched controls and their corresponding pooled ORs for each thrombophilia are shown in Table [1](#jah34477-tbl-0001){ref-type="table"}. In general, pooled ORs were similar irrespective of whether studies used age‐matched or non--age‐matched controls. However, significant associations were found in studies with age‐matched controls only.

###### 

Sensitivity Analysis of Studies That Used Age‐Matched versus Non--Age‐Matched Controls

  Thrombophilia             Age‐Matched Studies   Non--Age‐Matched Studies                                         
  ------------------------- --------------------- ----------------------------------------------------------- ---- -------------------
  FVL                       24                    1.58 (1.16--2.15)[\*](#jah34477-note-0003){ref-type="fn"}   32   1.09 (0.92--1.28)
  Homozygous FVL            19                    1.18 (0.51--2.71)                                           30   0.42 (0.17--1.08)
  Heterozygous FVL          19                    1.69 (1.19--2.40)[\*](#jah34477-note-0003){ref-type="fn"}   30   1.07 (0.89--1.28)
  PT G20210A mutation       22                    1.86 (1.38--2.49)[\*](#jah34477-note-0003){ref-type="fn"}   23   1.21 (0.90--1.61)
  Homozygous PTM            18                    0.27 (0.06--1.11)                                           21   0.33 (0.08--1.42)
  Heterozygous PTM          18                    1.91 (1.35--2.70)[\*](#jah34477-note-0003){ref-type="fn"}   21   1.10 (0.79--1.53)
  Protein C deficiency      9                     2.54 (1.21--5.37)[\*](#jah34477-note-0003){ref-type="fn"}   6    1.39 (0.44--4.33)
  Protein S deficiency      11                    2.28 (1.21--4.33)[\*](#jah34477-note-0003){ref-type="fn"}   6    2.30 (0.95--5.59)
  Antithrombin deficiency   7                     1.73 (0.70--4.28)                                           5    0.47 (0.09--2.38)

FVL indicates factor V Leiden; OR, odds ratio; PTM, prothrombin G20210A mutation.

Significant association.

### Geographic region {#jah34477-sec-0031}

Most studies were conducted in Europe (50%), Asia (19%), and North America (17%), with a smaller number from Africa (6%), Australia (3%), and South America (3%). Results were fairly consistent across geographic regions, except for the notably higher ORs for PCD and PSD in studies conducted in Asia (Table [2](#jah34477-tbl-0002){ref-type="table"}).

###### 

Sensitivity Analysis by Study Region

  Thrombophilia             Africa   Asia                  Australia   Europe                                                       North America   South America                                                                                                           
  ------------------------- -------- --------------------- ----------- ------------------------------------------------------------ --------------- --------------------- ---- ----------------------------------------------------------- ----- -------------------- ----- ---------------------
  FVL                       1        0.00 (0.00--259.67)   11          1.68 (1.08--2.61)[\*](#jah34477-note-0005){ref-type="fn"}    2               1.45 (0.37--5.70)     33   1.31 (1.08--1.58)[\*](#jah34477-note-0005){ref-type="fn"}   7     0.78 (0.52--1.18)    2     1.31 (0.39--4.33)
  Homozygous FVL            1        0.00 (0.00--197.19)   11          1.15 (0.37--3.61)                                            1               0.00 (0.00--201.44)   29   0.72 (0.35--1.50)                                           5     0.00 (0.00--23.31)   2     0.00 (0.00--116.06)
  Heterozygous FVL          1        0.00 (0.00--678.42)   11          1.51 (0.99--2.29)                                            1               0.30 (0.01--6.66)     29   1.32 (1.05--1.67)[\*](#jah34477-note-0005){ref-type="fn"}   5     0.68 (0.37--1.27)    2     1.32 (0.40--4.36)
  PTM                       1        2.32 (0.54--9.68)     7           0.90 (0.45--1.78)                                            2               2.33 (0.54--10.07)    28   1.57 (1.21--2.05)[\*](#jah34477-note-0005){ref-type="fn"}   6     1.35 (0.77--2.37)    1     2.00 (0.39--10.23)
  Homozygous PTM            1        0.00 (0.00--243.44)   7           0.18 (0.01--2.59)                                            1               0.00 (0.00--160.03)   24   0.34 (0.10--1.13)                                           5     0.36 (0.02--6.16)    1     0.00 (0.00--160.03)
  Heterozygous PTM          1        2.29 (0.54--9.76)     7           0.81 (0.39--1.67)                                            1               8.37 (0.23--308.69)   24   1.52 (1.12--2.08)[\*](#jah34477-note-0005){ref-type="fn"}   5     1.23 (0.64--2.37)    1     2.04 (0.40--10.36)
  Protein C deficiency      2        3.91 (0.75--20.44)    4           4.94 (1.52--16.06)[\*](#jah34477-note-0005){ref-type="fn"}   1               0.61 (0.09--4.19)     7    1.28 (0.46--3.55)                                           ···   ···                  ···   ···
  Protein S deficiency      3        1.83 (0.69--4.83)     4           7.46 (2.43--22.93)[\*](#jah34477-note-0005){ref-type="fn"}   1               0.73 (0.07--7.59)     7    1.96 (0.86--4.43)                                           1     1.05 (0.28--4.02)    ···   ···
  Antithrombin deficiency   1        5.22 (0.91--30.00)    3           0.60 (0.06--6.21)                                            1               1.26 (0.29--5.44)     7    0.75 (0.22--2.51)                                           ···   ···                  ···   ···

FVL indicates factor V Leiden; OR, odds ratio; PTM, prothrombin G20210A mutation.

Significant association.

### First‐ever ischemic stroke {#jah34477-sec-0032}

After the analysis was restricted to the 24 studies that exclusively enrolled cases with first‐ever ischemic stroke, the association with arterial ischemic stroke remained significant for PTM (OR, 1.46; 95% CI, 1.10--2.00) and PSD (OR, 3.58; 95% CI 1.12--11.42), but not for FVL (OR, 1.16; 95% CI, 0.92--1.47) or PCD (OR, 1.62; 95% CI, 0.51--5.40).

### Additional sensitivity analyses {#jah34477-sec-0033}

Sensitivity analyses were performed by excluding each of the following: studies with enriched case population (those who were referred for thrombophilia testing because of a clinical indication or recruited from a thrombophilia center),[19](#jah34477-bib-0019){ref-type="ref"}, [31](#jah34477-bib-0031){ref-type="ref"}, [39](#jah34477-bib-0039){ref-type="ref"} studies that used self‐reported history of stroke rather than imaging to define cases,[18](#jah34477-bib-0018){ref-type="ref"} studies that were rated as poor quality,[40](#jah34477-bib-0040){ref-type="ref"}, [41](#jah34477-bib-0041){ref-type="ref"}, [42](#jah34477-bib-0042){ref-type="ref"} and studies that reported inclusion of cases of recurrent ischemic stroke (but including studies that failed to report whether recurrent ischemic stroke was included or not).[26](#jah34477-bib-0026){ref-type="ref"}, [27](#jah34477-bib-0027){ref-type="ref"}, [28](#jah34477-bib-0028){ref-type="ref"} After each of these exclusions, the association of FVL, PTM, PCD, and PSD with arterial ischemic stroke remained significant, with similar pooled OR to the original analysis (Table [S9](#jah34477-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah34477-sec-0034}
==========

The results from our systematic review and meta‐analysis suggest that inherited thrombophilias, including FVL, PTM, PCD, and PSD, are associated with a significant but small increase in the risk of arterial ischemic stroke in adults (Figure [2](#jah34477-fig-0002){ref-type="fig"}), particularly in young patients (Figure [3](#jah34477-fig-0003){ref-type="fig"}). When studies with zero events in both groups were excluded from analysis, the association of FVL and PTM was stronger in the homozygous than in the heterozygous state, suggesting a potential dose‐response relationship and a causal role for inherited thrombophilia in arterial ischemic stroke.

Arterial ischemic stroke is a multicausal disease that involves complex interactions of genetic and environmental risk factors. Several lines of evidence implicate the coagulation pathway in the pathophysiological characteristics of arterial ischemic stroke. Increased levels of clotting proteins, such as factor VIII and factor XI, have been posited as independent risk factors for ischemic stroke.[43](#jah34477-bib-0043){ref-type="ref"}, [44](#jah34477-bib-0044){ref-type="ref"} Conversely, congenital deficiency of factors VIII, IX, and XI is protective against stroke and cardiovascular disease.[45](#jah34477-bib-0045){ref-type="ref"}, [46](#jah34477-bib-0046){ref-type="ref"} Anticoagulants reduce the risk of ischemic stroke. Compared with aspirin (the "standard of practice" in many studies for prevention of first or recurrent stroke), warfarin is noninferior for the secondary prevention of noncardioembolic ischemic stroke.[47](#jah34477-bib-0047){ref-type="ref"} Although rivaroxaban was not superior to aspirin in preventing recurrence after embolic stroke of undetermined source,[48](#jah34477-bib-0048){ref-type="ref"} the addition of rivaroxaban to aspirin reduced cardiovascular events, including stroke, in patients with stable atherosclerosis.[49](#jah34477-bib-0049){ref-type="ref"} Extended‐duration treatment with betrixaban for prevention of venous thrombosis among hospitalized medically ill patients reduced the risk of subsequent stroke.[50](#jah34477-bib-0050){ref-type="ref"}

Although inherited thrombophilias have not been traditionally recognized as risk factors for arterial thrombosis,[7](#jah34477-bib-0007){ref-type="ref"} there are several potential mechanisms by which they could contribute to arterial ischemic stroke. First, ischemic stroke may arise in the setting of deep vein thrombosis and subsequent paradoxical embolism via a PFO. In a prespecified subgroup analysis of subjects with PFO in our study, ischemic stroke was significantly associated with PTM, but not with other thrombophilias (Figure [3](#jah34477-fig-0003){ref-type="fig"}), possibly because of the limited number of studies in which PFO status was assessed. A previous meta‐analysis focusing on patients with PFO yielded similar results.[51](#jah34477-bib-0051){ref-type="ref"} Second, the unbalanced thrombin activation in individuals with inherited thrombophilia may contribute to formation and progression of atherosclerotic lesions through various mechanisms, including platelet activation, endothelial and vascular smooth muscle cell dysregulation, and recruitment of monocytes and macrophages.[52](#jah34477-bib-0052){ref-type="ref"}, [53](#jah34477-bib-0053){ref-type="ref"}

For FVL and PTM, our results are consistent with previous meta‐analyses. One report included 15 studies in FVL (pooled OR, 1.27; 95% CI, 0.86--1.87) and 10 studies in PTM (pooled OR, 1.30; 95% CI, 0.91--1.87).[54](#jah34477-bib-0054){ref-type="ref"} The association was more robust in young patients (aged \<55 years). In another meta‐analysis,[55](#jah34477-bib-0055){ref-type="ref"} only studies that enrolled young adults (aged \<50 years) were included. Among the 18 eligible studies, FVL was significantly associated with ischemic stroke (pooled OR, 1.89; 95% CI, 1.31--2.72). Although a meta‐analysis of PCD, PSD, and ATD has not previously been performed in adults, a meta‐analysis in children with arterial ischemic stroke identified a significant association with PCD (OR, 11.0; 95% CI, 5.13--23.59), but not with PSD (OR, 1.49; 95% CI, 0.32--6.92) or ATD (OR, 3.29; 95% CI, 0.70--15.48).[56](#jah34477-bib-0056){ref-type="ref"}

Genome‐wide association studies have identified genetic loci associated with stroke,[57](#jah34477-bib-0057){ref-type="ref"}, [58](#jah34477-bib-0058){ref-type="ref"} many of which share associations with other cardiovascular diseases, such as hypertension, atrial fibrillation, coronary artery disease, and venous thromboembolism. In the MEGASTROKE study, the weighted genetic risk score for venous thromboembolism was significantly associated with large‐artery atherosclerotic stroke and cardioembolic stroke, but not small‐vessel stroke.[57](#jah34477-bib-0057){ref-type="ref"} However, none of the inherited thrombophilias we investigated in the present study was significantly associated with stroke in genome‐wide association studies. This could be, in part, because of the inadequate statistical power to detect an association with rare variants in genome‐wide association studies, allelic heterogeneity inherent in certain thrombophilias (PCD, PSD, and ATD), and/or heterogeneity in stroke subtypes and ethnicity of the study populations. Interestingly, data extracted from multiple genome‐wide association studies have shown that genetic variants indicative of high protein C level were associated with lower risk of coronary artery disease/myocardial infarction,[59](#jah34477-bib-0059){ref-type="ref"} suggesting a potential role for natural anticoagulants in the pathogenesis of arterial thrombosis. A similar analysis for arterial ischemic stroke would be an insightful topic for future studies.

Among the studies included in our analysis, interstudy heterogeneity was low, with I^2^ values ranging from 0% to 35%, suggesting that the results could appropriately be combined. Sources of heterogeneity among studies included the following: study population (number of participants, age groups, geographic region and ethnicity, baseline clinical risk of stroke, and presence of comorbidities); outcome measurement (methods of stroke diagnosis and types of stroke included); and exposure measurement (thrombophilia test methods, timing of testing after stroke in cases, and exclusion of patients taking anticoagulants).

From our sensitivity analysis by study region, the ORs for PCD and PSD were notably higher in studies conducted in Asia than other regions (Table [2](#jah34477-tbl-0002){ref-type="table"}). These disparities could be, in part, because of differences in the prevalence of inherited thrombophilias in different regions. For example, PCD, PSD, and ATD have been reported to be more common in the Asian population than in whites.[60](#jah34477-bib-0060){ref-type="ref"}, [61](#jah34477-bib-0061){ref-type="ref"}, [62](#jah34477-bib-0062){ref-type="ref"} In one included study from Taiwan,[63](#jah34477-bib-0063){ref-type="ref"} the prevalence of these natural anticoagulant deficiencies was distinctly high, affecting 27% of the cases.

Our study has several limitations. First, because this is a meta‐analysis of case‐control studies, the results may be affected by biases inherent to case‐control studies, including selection bias and misclassification bias. In a small number of studies, controls were not drawn from the same population as cases. For instance, cases were recruited from patients referred for clinical thrombophilia testing, whereas controls were recruited from a population without a history of thrombosis in 3 studies.[19](#jah34477-bib-0019){ref-type="ref"}, [31](#jah34477-bib-0031){ref-type="ref"}, [39](#jah34477-bib-0039){ref-type="ref"} In such studies, the presence of inherited thrombophilia in the cases may be overrepresented because of selection bias. In most studies in which clinical stroke risk factors were reported in both cases and controls, the risk factors were more prevalent in cases than controls. These imbalances could have confounded the results of these studies. Moreover, cases with recurrent stroke were included in a few studies,[26](#jah34477-bib-0026){ref-type="ref"}, [27](#jah34477-bib-0027){ref-type="ref"}, [28](#jah34477-bib-0028){ref-type="ref"} possibly resulting in overrepresentation of thrombophilia in the cases for such studies. However, a sensitivity analysis excluding these 3 studies reassuringly yielded similar results to the original analysis. Misclassification of exposure status could have arisen if the exposure assessors were not blinded or if there were confounders that influenced the results of thrombophilia testing. This is especially true in the case of natural anticoagulant deficiencies (PCD, PSD, and ATD), where thrombophilia status was defined by phenotypic assays as opposed to genetic testing. Acute thrombosis, including stroke, may cause acquired natural anticoagulant deficiencies and lead to the appearance of higher frequencies of such conditions in stroke cases. However, most studies avoided this issue by requiring repeated testing after the short‐term phase to define deficiencies. The use of anticoagulants and the presence of certain medical conditions (eg, liver disease) can also cause acquired deficiencies of natural anticoagulants. Attempts to account for these factors varied between studies. Second, we were not able to perform subgroup analyses by ethnicity or stroke subtype because of a lack of disaggregated data for these variables. Finally, although we found a significant association between inherited thrombophilia and ischemic stroke, this cannot be taken as evidence of a causal relationship nor can it be considered supportive of thrombophilia testing in clinical practice. Further studies are needed to determine whether thrombophilia testing in patients with otherwise unexplained arterial ischemic stroke is beneficial and whether and how the results should influence management.

Despite its limitations, our study has several strengths. First, our meta‐analysis included the largest number of studies and participants to date. Second, to minimize publication bias, our literature search included "gray literature," such as conference abstracts and letters to editors. Third, the included studies originated from a wide range of geographic regions and the results may, therefore, be applicable to clinicians and patients around the world.

Conclusions {#jah34477-sec-0035}
===========

Our systematic review and meta‐analysis demonstrates an association between multiple inherited thrombophilias and the risk of arterial ischemic stroke in adults. Further studies are needed to determine whether inherited thrombophilias have an impact on clinical outcomes, such as recurrent stroke, and whether the finding of inherited thrombophilia should influence clinical management of patients with arterial ischemic stroke.
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